The enteric microbiota contribute to gastrointestinal health, and their disruption has been associated with many disease states. Some patients consume probiotic products in attempts to manipulate the intestinal microbiota for health benefit. It is important for gastroenterologists to improve their understanding of the mechanisms of probiotics and the evidence that support their use in practice. Clinical trials have assessed the therapeutic effects of probiotic agents for several disorders, including antibiotic- or Clostridium difficile-associated diarrhea, irritable bowel syndrome, and the inflammatory bowel diseases. Although probiotic research is a rapidly evolving field, there are sufficient data to justify a trial of probiotics for treatment or prevention of some of these conditions. However, the capacity of probiotics to modify disease symptoms is likely to be modest and varies among probiotic strains-not all probiotics are right for all diseases. The current review provides condition-specific rationale for using probiotic therapy and literature-based recommendations.

Original languageEnglish
Pages (from-to)960-968
Number of pages9
JournalClinical Gastroenterology and Hepatology
Issue number9
StatePublished - Sep 2012


  • Clostridium difficile
  • Crohn's Disease and Colitis
  • IBD
  • IBS
  • Pouchitis
  • Yogurt


Dive into the research topics of 'A Gastroenterologist's Guide to Probiotics'. Together they form a unique fingerprint.

Cite this